This fully agrees with the results obtained in another independent study in melanoma patients, where it was observed that BTLA expression was reduced during differentiation of CD8+ T lymphocytes to effector cells, whereas in vivo expression was maintained in those lymphocytes specific for melanoma tumor antigens hindering their antitumor activity [77]. This evidence concerns the gene CD8A and melanoma.